ARCHIVES

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Sporn Wins BMS Cancer Research Award; Dana-Farber To Try To Affect Teen Health

April 3, 1998

More Concept Approvals By DCPC Board

May 18, 1984

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

New Trial For Metastatic Colorectal Cancer Testing Vaccine-Chemotherapy Combination

March 29, 2002

CTAC Discussion, Group Chairs Comment

December 17, 2010

Arizona Cancer Center Seeks NCI Recognition As Comprehensive

May 29, 1987